Inpatient Treatment of Community-Acquired Pneumonia
For adults hospitalized with community-acquired pneumonia on a medical ward, initiate empiric therapy with either a respiratory fluoroquinolone (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily) OR a β-lactam (ceftriaxone 1-2g daily, cefotaxime 1-2g every 8 hours, or ampicillin-sulbactam 1.5-3g every 6 hours) plus a macrolide (azithromycin 500 mg daily or clarithromycin 500 mg twice daily). 1
Treatment Algorithm by Severity
Non-ICU Hospitalized Patients (Medical Ward)
The choice between monotherapy and combination therapy depends on recent antibiotic exposure and local resistance patterns:
Preferred regimens (strong recommendation, level I evidence):
- Respiratory fluoroquinolone alone (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily) 1
- β-lactam PLUS macrolide combination 1
- β-lactams: ceftriaxone 1-2g daily, cefotaxime 1-2g every 8 hours, or ampicillin-sulbactam 1.5-3g every 6 hours
- Macrolides: azithromycin 500 mg daily (preferred) or clarithromycin 500 mg twice daily
For penicillin-allergic patients: Use a respiratory fluoroquinolone 1
If recent antibiotic therapy within 90 days: Select a different antibiotic class than previously used 2
ICU/Severe Pneumonia Patients
Combination therapy is mandatory for severe CAP (strong recommendation):
Standard Severe CAP (No Pseudomonas Risk)
- β-lactam (ceftriaxone, cefotaxime, or ampicillin-sulbactam) PLUS either:
- Azithromycin (level II evidence), OR
- Respiratory fluoroquinolone (level I evidence) 1
With Pseudomonas Risk Factors
Risk factors include: structural lung disease (bronchiectasis), recent hospitalization, recent broad-spectrum antibiotics
Use antipseudomonal coverage (moderate recommendation, level III evidence):
- Antipseudomonal β-lactam (piperacillin-tazobactam 4.5g every 6 hours, cefepime 2g every 8 hours, imipenem 500 mg every 6 hours, or meropenem 1g every 8 hours) PLUS either:
- Ciprofloxacin 400 mg IV every 8 hours or levofloxacin 750 mg IV daily, OR
- Aminoglycoside (gentamicin 5-7 mg/kg daily, tobramycin 5-7 mg/kg daily, or amikacin 15-20 mg/kg daily) PLUS azithromycin or respiratory fluoroquinolone 1
With MRSA Risk Factors
Risk factors include: prior IV antibiotic use within 90 days, hospitalization in units where >20% of S. aureus isolates are methicillin-resistant, or high mortality risk
Add MRSA coverage (strong recommendation, low-quality evidence):
- Vancomycin 15 mg/kg IV every 8-12 hours (target trough 15-20 mg/mL; consider loading dose 25-30 mg/kg for severe illness), OR
- Linezolid 600 mg IV every 12 hours 3, 1, 4
Critical Management Principles
Timing of Antibiotic Administration
- Initiate antibiotics immediately upon diagnosis, preferably while still in the emergency department (moderate recommendation, level III evidence) 1
- For patients with septic shock, antibiotics should be given as soon as possible 5
IV to Oral Transition
Switch from IV to oral therapy when the patient meets ALL criteria (strong recommendation, level II evidence):
- Hemodynamically stable
- Clinically improving
- Able to ingest medications
- Normally functioning gastrointestinal tract
- Afebrile for 48-72 hours 1
Use the same antibiotic class when switching to oral therapy to maintain coverage. The European guidelines specifically note that switching to a different class (commonly levofloxacin) is discordant with recommendations 6.
Duration of Therapy
Treat for a minimum of 5 days (level I evidence), ensuring the patient is:
- Afebrile for 48-72 hours, AND
- Has no more than 1 sign of clinical instability before discontinuation (moderate recommendation, level II evidence) 1
The European guidelines recommend treatment should generally not exceed 8 days in responding patients 5. Recent evidence supports even shorter durations (3 days) for patients achieving clinical stability by day 3 7.
Longer duration needed if:
- Initial therapy was not active against identified pathogen
- Complicated by extrapulmonary infection (meningitis, endocarditis)
- Slow clinical response 1
Common Pitfalls to Avoid
Avoid monotherapy with macrolides alone for hospitalized patients—resistance rates make this inadequate 1
Do not routinely obtain sputum cultures unless severe pneumonia, ICU admission, or failure of outpatient therapy—only 45% yield evaluable samples and 16% identify pathogens when obtained after antibiotic initiation 6
Avoid unnecessarily prolonged treatment—median durations of 10 days are common in practice but exceed guideline recommendations, contributing to antibiotic resistance 6
Do not use two β-lactams together—this provides no additional benefit 3
For penicillin-allergic patients requiring antipseudomonal coverage, substitute aztreonam for the β-lactam 1
Special Considerations
Hospital-Acquired Pneumonia (HAP)
If pneumonia develops ≥48 hours after hospital admission, follow HAP guidelines rather than CAP guidelines. Empiric therapy should be based on local antibiograms and include coverage for S. aureus (MRSA if risk factors present) 3.
Influenza with Bacterial Superinfection
During influenza season, test for influenza and treat with oseltamivir PLUS antibacterial agents targeting S. pneumoniae and S. aureus 1
Biomarker-Guided Therapy
Procalcitonin may guide shorter treatment duration but should NOT be used to withhold antibiotic initiation in clinically suspected CAP (strong recommendation, moderate quality evidence) 4